330 related articles for article (PubMed ID: 18840134)
1. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
Fujita Y; Hiramatsu M; Kawai M; Sumiyoshi K; Nishimura H; Tanigawa N
Dis Esophagus; 2008; 21(6):496-501. PubMed ID: 18840134
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer.
Kanekiyo S; Takeda S; Nakajima M; Nishiyama M; Kitahara M; Shindou Y; Michihisa I; Abe T; Yoshino S; Hazama S; Nagano H
Anticancer Res; 2016 Apr; 36(4):1923-7. PubMed ID: 27069181
[TBL] [Abstract][Full Text] [Related]
4. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.
Akutsu Y; Shuto K; Kono T; Uesato M; Hoshino I; Shiratori T; Miyazawa Y; Isozaki Y; Akanuma N; Matsubara H
Hepatogastroenterology; 2012 Oct; 59(119):2095-8. PubMed ID: 22328303
[TBL] [Abstract][Full Text] [Related]
5. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
Jin J; Xu X; Wang F; Yan G; Liu J; Lu W; Li X; Tucker SJ; Zhong B; Cao Z; Wang D
J Thorac Oncol; 2009 Aug; 4(8):1017-21. PubMed ID: 19542899
[TBL] [Abstract][Full Text] [Related]
6. A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
Nakajima Y; Kawada K; Tokairin Y; Hoshino A; Okada T; Kawano T
Dig Surg; 2018; 35(2):131-137. PubMed ID: 28554183
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.
Yoshioka T; Sakayori M; Kato S; Chiba N; Miyazaki S; Nemoto K; Shibata H; Shimodaira H; Ohtsuka K; Kakudo Y; Sakata Y; Ishioka C
Int J Clin Oncol; 2006 Dec; 11(6):454-60. PubMed ID: 17180514
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study.
Ohnuma H; Sato Y; Hayasaka N; Matsuno T; Fujita C; Sato M; Osuga T; Hirakawa M; Miyanishi K; Sagawa T; Fujikawa K; Ohi M; Okagawa Y; Tsuji Y; Hirayama M; Ito T; Nobuoka T; Takemasa I; Kobune M; Kato J
Cancer Sci; 2018 Nov; 109(11):3554-3563. PubMed ID: 30137686
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting.
Osaka Y; Takagi Y; Hoshino S; Tachibana S; Tsuchida A; Aoki T
Dis Esophagus; 2006; 19(6):473-6. PubMed ID: 17069591
[TBL] [Abstract][Full Text] [Related]
11. A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer.
Nakajima Y; Suzuki T; Haruki S; Ogiya K; Kawada K; Nishikage T; Nagai K; Kawano T
Hepatogastroenterology; 2008; 55(86-87):1631-5. PubMed ID: 19102357
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H
Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
[TBL] [Abstract][Full Text] [Related]
14. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Miyawaki Y; Nakajima Y; Kawada K; Okada T; Tokairin Y; Kawano T
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27001629
[TBL] [Abstract][Full Text] [Related]
16. Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis.
Kushida T; Nohara S; Yoshino K; Fujiwara D; Ouchi K; Amano T; Isayama F; Tomita N; Iwanuma Y; Sasai K; Tsurumaru M; Kajiyama Y
Dis Esophagus; 2014; 27(4):368-73. PubMed ID: 23865505
[TBL] [Abstract][Full Text] [Related]
17. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
Tanaka T; Fujita H; Sueyoshi S; Tanaka Y; Sasahara H; Mori N; Nagano T; Yamana H; Shirouzu K
Chemotherapy; 2007; 53(6):449-53. PubMed ID: 17952006
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
Yamazaki K; Hironaka S; Boku N; Yasui H; Fukutomi A; Yoshino T; Onozawa Y; Hasuike N; Inui T; Yamaguchi Y; Ono H
Int J Clin Oncol; 2008 Apr; 13(2):150-5. PubMed ID: 18463960
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
Lyu X; Huang J; Mao Y; Liu Y; Feng Q; Shao K; Gao S; Jiang Y; Wang J; He J
J Surg Oncol; 2014 Dec; 110(7):864-8. PubMed ID: 24976079
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.
Zhang F; Wang Y; Wang ZQ; Sun P; Wang DS; Jiang YX; Zhang DS; Wang FH; Xu RH; Li YH
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27868295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
